Pentixapharm presents first-in-human data on Lu177-PentixaTher for Muscle-Invasive Bladder Cancer at ASCO-GU 2025, showing potential for bladder preservation and targeted treatment ...
The NAGA Group's research update by Warburg maintains 'BUY' recommendation & adjusts price target. Analysts highlight improved profitability post-merger with CAPEX.com ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback